Clinical Study

A Phase 2 Evaluation Of Trc105 In Combination With Bevacizumab For The Treatment Of Recurrent Or Progresisve Gliblastoma That Has Progressed On Bevaci

Posted Date: May 15, 2019

  • Investigator: Rekha Chaudhary
  • Type of Study: Drug

This study will determine if tumors shrink or if patients survive longer with TRC105 monoclonal antibody treatment in combination with bevacizumab, after his/her tumor has already grown while receiving bevacizumab treatment. The study will also evaluate how well patients tolerate the combination of

Criteria:

Eligible Patients Must Have Glioblastoma That Has Come Back Or Progressed While On Anti-Angiogenic T

Keywords:

105Gm-201, Brain Cancer, Brain Tumor, Gbm, Neuro-Oncology

For More Information:

Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu